XTX Topco Ltd Raises Stock Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

XTX Topco Ltd grew its holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) by 142.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 171,463 shares of the company’s stock after buying an additional 100,679 shares during the period. XTX Topco Ltd owned approximately 0.17% of Unicycive Therapeutics worth $136,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Virtu Financial LLC grew its stake in shares of Unicycive Therapeutics by 566.8% in the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after buying an additional 62,881 shares in the last quarter. 40.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on UNCY. Guggenheim began coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They set a “buy” rating and a $6.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target on shares of Unicycive Therapeutics in a research note on Friday, April 11th.

Unicycive Therapeutics Trading Down 0.7 %

UNCY stock opened at $0.64 on Wednesday. The stock has a market cap of $77.09 million, a PE ratio of -0.66 and a beta of 2.15. Unicycive Therapeutics, Inc. has a 12 month low of $0.20 and a 12 month high of $1.25. The company has a 50-day moving average price of $0.58 and a 200 day moving average price of $0.60.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Sell-side analysts forecast that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.